Real-world analysis of adherence to abemaciclib and endocrine therapy in women with HR+/HER2- breast cancer

A retrospective analysis investigated adherence to abemaciclib plus endocrine therapy among patients with HR+ HER2- breast cancer. The results indicated that adherence is high in a real-life setting but is dependent on proactive patient management, including providing careful evaluation of patients and detailed information about expected adverse events.